A phase I study of sequential irinotecan and5-fluorouracil/leucovorin
نویسندگان
چکیده
منابع مشابه
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
BACKGROUND Irinotecan (CPT-11) and 5-fluorouracil (5-FU)/leucovorin are active agents in colorectal cancer. A sequence-dependent synergism of SN-38 followed by 5-FU/leucovorin in vitro led us to conduct a phase I trial of CPT-11 followed by 5-FU/leucovorin to determine the maximum tolerated dose (MTD) and toxicities of this regimen and to obtain preliminary indications of its activity in patien...
متن کاملA phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
A Phase I trial of irinotecan was performed to determine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and the incidence and severity of other toxicities in children with refractory solid tumors. Thirty-five children received 146 courses of irinotecan administered as a 60-min i.v. infusion, daily for 5 days, every 21 days, after premedication with dexamethasone and onda...
متن کاملA Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
mTOR inhibitors are emerging as important anti-neoplastic agents with a wide range of clinical applications. The topoisomerase I inhibitor irinotecan is a potent DNA damaging drug, with a broad spectrum of anticancer activities. mTOR appears to enhance cancer cell survival following DNA damage, thus the inhibition of mTOR after irinotecan could theoretically show synergistic activities in patie...
متن کاملa study of translation of english litrary terms into persian
چکیده هدف از پژوهش حاضر بررسی ترجمه ی واژه های تخصصی حوزه ی ادبیات به منظور کاوش در زمینه ی ترجمه پذیری آنها و نیز راهکار های به کار رفته توسط سه مترجم فارسی زبان :سیامک بابایی(1386)، سیما داد(1378)،و سعید سبزیان(1384) است. هدف دیگر این مطالعه تحقیق در مورد روش های واژه سازی به کار رفته در ارائه معادل های فارسی واژه های ادبی می باشد. در راستای این اهداف،چارچوب نظری این پژوهش راهکارهای ترجمه ار...
15 صفحه اولIrinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
The combination of irinotecan (Camptosar), epirubicin, and capecitabine (Xeloda) has shown an acceptable toxicity profile. In this open-label phase I study, irinotecan was administered IV at a fixed dose of 250 mg/m2 on day 1 in combination with capecitabine at a fixed dose of 1500 mg/m2 for days 2 to 7 and epirubicin starting at a dose of 40 mg/m2 and escalating by 10 mg/m2 in cohorts of three...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2002
ISSN: 0923-7534
DOI: 10.1093/annonc/mdf260